Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Molecular Partners Ag ADR (MOLN)

Molecular Partners Ag ADR (MOLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 187,744
  • Shares Outstanding, K 40,375
  • Annual Sales, $ 5,650 K
  • Annual Income, $ -61,390 K
  • EBIT $ -71 M
  • EBITDA $ -68 M
  • 60-Month Beta 1.07
  • Price/Sales 18,774.40
  • Price/Cash Flow N/A
  • Price/Book 1.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.36
  • Low Estimate -0.40
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.96 +17.28%
on 01/21/26
4.75 -2.11%
on 02/05/26
+0.55 (+13.41%)
since 01/09/26
3-Month
3.92 +18.62%
on 12/15/25
4.75 -2.11%
on 02/05/26
+0.62 (+15.38%)
since 11/11/25
52-Week
3.36 +38.39%
on 04/29/25
5.10 -8.82%
on 03/07/25
-0.27 (-5.49%)
since 02/11/25

Most Recent Stories

More News
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancers Dosimetry data highlight Radio-DARPins as vector...

MOLN : 4.65 (-1.90%)
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026 Full imaging and dosimetry data from MP0712 compassionate care program...

MOLN : 4.65 (-1.90%)
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built...

MOLN : 4.65 (-1.90%)
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics

Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry...

MOLN : 4.65 (-1.90%)
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimens Accelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure...

MOLN : 4.65 (-1.90%)
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid...

MOLN : 4.65 (-1.90%)
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...

MOLN : 4.65 (-1.90%)
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells...

MOLN : 4.65 (-1.90%)
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025  First patient...

MOLN : 4.65 (-1.90%)
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected...

MOLN : 4.65 (-1.90%)

Business Summary

Molecular Partners AG is a clinical-stage biotech company. It involved in developing a new class of custom-built protein drugs known as DARPin(R) therapeutics. Molecular Partners AG is based in SWITZERLAND.

See More

Key Turning Points

3rd Resistance Point 4.77
2nd Resistance Point 4.74
1st Resistance Point 4.70
Last Price 4.65
1st Support Level 4.63
2nd Support Level 4.60
3rd Support Level 4.56

See More

52-Week High 5.10
Last Price 4.65
Fibonacci 61.8% 4.44
Fibonacci 50% 4.23
Fibonacci 38.2% 4.02
52-Week Low 3.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar